Frank Stokes, Chief Financial Officer of Castle Biosciences Inc., filed a Form 4 with the SEC on August 18, 2026, disclosing the sale of 24,908 shares of common stock on August 14, 2026.
Key Highlights
- Shares sold: Frank Stokes disposed of 24,908 shares of Castle Biosciences common stock on August 14, 2026.
- Weighted-average price: The reported sale price was $29.77 per share, reflecting a weighted average across multiple trades.
- Price range: Individual trades were executed at prices ranging from $29.71 to $29.97, inclusive.
- Remaining ownership: Following the transaction, Stokes directly beneficially owned 35,177 shares of common stock.
- Transaction code: The sale was coded "S" (open-market sale) in Table I of the filing.
- Issuer and exchange: The issuer is Castle Biosciences Inc., listed as NASDAQ:CSTL.
CFO Frank Stokes Discloses Open-Market Sale of Castle Biosciences Shares
According to the Form 4 filed August 18, 2026, Frank Stokes, identified in the filing as Chief Financial Officer of Castle Biosciences Inc. (NASDAQ:CSTL), reported a disposition of 24,908 shares of common stock on August 14, 2026. The transaction was classified with code "S," indicating an open-market sale. The filing notes that the transaction was carried out in multiple trades, with individual prices ranging from $29.71 to $29.97, inclusive, and a weighted-average sale price of $29.77 per share.
The filing further states that Stokes "hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected." No derivative securities transactions were reported in Table II of the filing.
Following the reported sale, Stokes held direct beneficial ownership of 35,177 shares of Castle Biosciences common stock, according to the filing. The Form 4 was signed by Frank Stokes as attorney-in-fact and bears a filing date of August 18, 2026. The date of earliest transaction is listed as August 14, 2026. No amendment date was indicated, meaning this is not a corrected filing.
What Was Disclosed
Castle Biosciences CFO Frank Stokes disclosed an open-market sale of 24,908 shares of common stock at a weighted-average price of $29.77, executed on August 14, 2026, leaving him with direct beneficial ownership of 35,177 shares.



Please wait processing your request...